Skip to content

In the BioHarmony Drug Report Database


Hepcludex (bulevirtide) is a protein pharmaceutical. Bulevirtide was first approved as Hepcludex on 2020-07-31. It has been approved in Europe to treat chronic hepatitis d.
Trade Name Hepcludex
Common Name Bulevirtide
Indication chronic hepatitis d
Drug Class Peptides: antiviral peptides; antivirals
Get full access now